ImmunoGen Stock News

ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of high

Sep 22, 2020 (The Expresswire) -- Global “Follicular Lymphoma Treatment Market” Report discusses about the important developments impacting and increasing...

ADC Therapeutics SA (NYSE : ADCT), une société de biotechnologie spécialisée dans l'oncologie au stade clinique avancé, pionnière dans le développemen

ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of hig

Edo 2020 Governorship elections as uploaded on the Independent National Electoral Commission (INEC) portal.

The African Democratic Congress (ADC) in Ondo West and East Federal constituency of Ondo State has collapsed its structure into the All Progressives Congress (APC). The ADC led by Wale Akinlosotu and

Tudor Investment Corp Et Al acquired a new stake in shares of ImmunoGen, Inc. (NASDAQ:IMGN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm a

ImmunoGen Presents Final Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin® at ESMO

Synaffix announces promising findings from its latest in vivo benchmarking study, and the data will be presented at the World ADC Digital conference.

With the recently announced $21B acquisition of Immunomedics, and Merck's multi-billion-dollar investment in Seattle Genetics, the ADC (antibody-drug conjugate) space is a white hot sector in oncology

Gilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU) announced today that the companies have entered into a definitive agreement pursu

ADC Therapeutics SA (NYSE : ADCT), une société de biotechnologie dédiée à l'oncologie au stade clinique avancé, pionnière du développement et de la co

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive a milestone payment from GlaxoSmithKline (GSK) triggered by European Commiss

ImmunoGen is a turnaround stock that has tremendous potential. After temporary regulatory and clinical setbacks, the company is on a vigorous campaign for a change.